U.S. IT Stock News

NYSE:RKT
NYSE:RKTDiversified Financial

Rocket Companies Faces Cooling Housing Market As Investor Purchases Slide

Investor home purchases and pending home sales have dropped to their lowest levels since 2020, according to recent Rocket-powered reports. High home prices, elevated mortgage rates, and wider economic uncertainty are contributing to weaker housing activity. These housing trends are important for Rocket Companies, which is closely tied to U.S. mortgage and housing transaction volumes. Rocket Companies (NYSE:RKT) sits at the center of this cooling housing market, with its business closely...
NasdaqGS:CRSR
NasdaqGS:CRSRTech

Is It Too Late To Consider Corsair Gaming (CRSR) After Its Recent Share Price Surge

If you are wondering whether Corsair Gaming stock is priced attractively after a volatile few years, this article breaks down what the current share price might be implying about value. The stock has recently moved sharply, with returns of 57.7% over the past week, 74.4% over the past month, and 101.7% year to date, while the 1 year return is 38.1% and longer 3 and 5 year periods show declines of 38.9% and 61.9% respectively. These swings have put Corsair Gaming back on watchlists,...
NasdaqGS:CHA
NasdaqGS:CHAHospitality

Chagee Holdings (CHA) Margin Slide Challenges Bullish Growth Narrative After Q1 2026 Results

Chagee Holdings (NasdaqGS:CHA) opened Q1 2026 with revenue of C¥3.5b and basic EPS of C¥2.36, alongside net income excluding extra items of C¥450.33m, as the stock trades around $12.76. The company has seen quarterly revenue move from C¥3.39b in Q1 2025 to C¥3.55b in Q1 2026, while basic EPS shifted from C¥6.58 to C¥2.36 over the same period. This sets up a picture where topline scale is paired with changing per share profitability. For investors, a key consideration is how to weigh that...
NasdaqGS:AGIO
NasdaqGS:AGIOBiotechs

Agios Halts Tebapivat Trials As Sickle Cell Focus Shapes Valuation

Agios Pharmaceuticals halted development of tebapivat in lower risk myelodysplastic syndromes after a Phase 2b trial did not meet internal efficacy thresholds. The decision removes a candidate from Agios’s rare blood disorder pipeline and follows a review of trial data against the company’s internal benchmarks. Agios plans to continue concentrating resources on its sickle cell disease program and broader portfolio in rare hematologic conditions. For investors tracking NasdaqGS:AGIO, the...
NYSE:LUMN
NYSE:LUMNTelecom

Lumen’s Alkira Deal Shifts Focus Toward Cloud Growth And Valuation Risk

Lumen Technologies (NYSE:LUMN) announced the acquisition of Alkira, a cloud-native networking platform provider. The transaction is intended to accelerate Lumen's digital platform strategy and expand its cloud and networking capabilities. The deal marks a shift in focus toward growth initiatives beyond Lumen's legacy telecom services. Lumen Technologies operates as a communications and digital infrastructure company, and this move directs more of its focus toward cloud networking and...
NasdaqGS:BPOP
NasdaqGS:BPOPBanks

AM Best Rating Reaffirmation Supports Popular Valuation Case For Investors

AM Best affirmed the financial strength and issuer credit ratings of Popular Life Re, a subsidiary of Popular, Inc., with a stable outlook. The decision reflects AM Best’s view of Popular Life Re’s capital position and risk management profile. This ratings affirmation is relevant for investors tracking Popular’s insurance operations under ticker NasdaqGS:BPOP. For Popular, which trades on NasdaqGS:BPOP, this ratings affirmation comes as the stock changes hands at $148.53. The company has...
NYSE:EARN
NYSE:EARNCapital Markets

Ellington Credit (EARN) TTM Loss Of US$38.9 Million Challenges High Yield Bull Case

Ellington Credit (EARN) just wrapped up FY 2026 with Q4 total revenue of US$10.0 million and basic EPS of US$0.86 loss, while the trailing twelve months show total revenue of US$43.5 million and basic EPS of US$1.03 loss. Over recent periods, the company has seen quarterly revenue move between US$9.98 million and US$29.0 million, with basic EPS ranging from a profit of about US$0.19 to a loss of roughly US$0.86, giving a mixed read on earnings quality and payout capacity. For investors, that...